TNFRSF17 and Miyoshi myopathy: Recent studies (2024–2025) have demonstrated that genetically or chemically modified exosomes, such as anti-BCMA-engineered variants, can higher uptake efficiency in MM models by tailoring surface composition and enabling targeted drug delivery (e.g., bortezomib) [330,331].